Zota Health Care Ltd reported a 7.1% quarter-on-quarter (QoQ) increase in its consolidated revenues for the quarter-ended Dec (Q3FY25). On a year-on-year (YoY) basis, it witnessed a growth of 54.3%.
Its expenses for the quarter were up by 13.2% QoQ and 82.9% YoY.
The net profit increased 55.5% QoQ and increased 544.2% YoY.
The earnings per share (EPS) of Zota Health Care Ltd declined at 6.3 during Q3FY25.
Zota Health Care Limited is a renowned pharmaceutical company that manufactures, markets, and exports pharmaceutical, ayurvedic, nutraceutical, and overthecounter (OTC) products. The Company was incorporated in July 12, 2000 and is based out of Surat, Gujarat. The Company meets the requirements of millions of people by increasing access to highquality, affordable medicines for chronic illnesses including heart disease, diabetes, thyroid disease, and others, giving Indias pharmaceutical industry a boost.The Company has three business verticals: Marketinga traditional business vertical, and driving business verticals Exports and Retail harmacy Chain. Through its chain, Davaindia, the largest privatesector generic pharmacy chain, the Company is making strong inroads into the generic retail pharmacy business. The Companys stateoftheart manufacturing facility at Sachin SEZ serves customers in more than 30 countries. Davaindia is a retail generic pharmacy chain whose core value proposition is providing quality generic medicines at substantial discounts, i.e. 30% to 90%, to their branded equivalents. Davaindia focuses on privatelabel products in the medicinal, OTC, and ayurvedic categories, with a greater emphasis on chronic therapies and ailments.The Marketing business vertical involves the direct distribution of generic drugs, OTC products, and other pharmaceutical products through the Companys distribution network across India. In domestic Marketing business, the Company procures finished dosage forms (FDFs) from domestic formulation manufactures and then market them under its portfolio of brands. It has a set of manufacturing partners recognized by the WHO with a rigorous focus on product quality. With a portfolio of more than 3000 products in various categories, such as generics, OTC products, allopathic, ayurvedic, etcetera, the Company cater to a variety of ailments. Currently, the Company has over 1050 distributors spread around the country. Instead of the Company directly engaging in sales, distribution, and promotion activities, its distributors engage in ethical marketing or other sales, distribution, and promotion activities on their own. Instead, it provide distributors directly with incentives to help them sell products more effectively.Secondly, the exports business vertical started in 2010, following the establishment of formulations manufacturing facility in the Sachin SEZ. The Company is required to export products from this unit in accordance with the laws governing this SEZ. At present, it has product approvals in 30 countries, particularly in the semiregulated and regulated markets in the African, Asian, CIS, and Latin American countries. In this facility, the Company make around 250 formulations for direct exports and contract manufacturing. . At present, the Company has 253 dossiers approved across multiple countries, and another 311 dossiers have been filed and are pending approval. It significantly increased efforts and investments towards product registration, the results of which are now apparent in the form of product approvals and expansion of export operations. In the Retail Pharmacy Chain business vertical, the Company operates a chain of pharmacy stores under the brand Davaindia. Davaindia focuses only on privatelabel products in the medicinal, OTC, and ayurvedic categories, with a greater emphasis on chronic therapies and ailments. This concept started with three pilot stores in 2017 and has been scaled up to become the largest privatesector generic pharmacy chain with more than 591 stores as of March 2021. Davaindia operates on a unique assetlight franchise model for majority stores. These stores are engaged in exclusive sales of Davaindia products, with more than 95% of products being privatelabel. In all areas and media, such as TV commercials, printing, digital social media, radio, among others, the Company has undertaken bold and aggressive marketing and promotion activities with the firm intention of creating topofthemind brand recall for Davaindia. Davaindia being a frontrunner in private sector generic pharmacy assumed the responsibility to create awareness, propagate virtues and debunk misconceptions about generic drugs. In 2019, the Company opened 150 Davaindia outlets. Davaindia expanded to over 250 outlets, becoming the fastestgrowing privatesector generic pharmacy chain in India in 2020.
How has Zota Health Care shares performed in the past ?
Zota Health Care share price in the past 1-year return was 68.19. The Zota Health Care share hit a 1-year low of Rs. 440.1 and a 1-year high of Rs. 1078.
What is the market cap of Zota Health Care ?
The market cap of Zota Health Care is Rs. 2225.95 Cr. as of 24/3/2025.
What is the current P/E ratio of Zota Health Care ?
The PE ratios of Zota Health Care is 357.23 as of 24/3/2025.
What is the current PB ratio of Zota Health Care ?
The PB ratios of Zota Health Care is 9.76 as of 24/3/2025
What is the Mutual Fund shareholding in Zota Health Care ?
The Mutual Fund Shareholding in Zota Health Care was 0.03% at the end of 24/3/2025.
How to buy Zota Health Care shares?
You can easily buy Zota Health Care shares in Kotak Securities by opening a demat account and getting the KYC documents verified online.
Please be aware that Zota Health Care stock prices are subject to continuous fluctuations due to various factors.